Practical Considerations When Moving Manufacturing Sites into or out of the UK Practical Considerations When Moving Manufacturing Sites into or out of the UK The globalization of the pharmaceutical supply chain presents several challenges and opportunities for manufacturers, especially in light of the ever-evolving regulatory landscape. A significant regulatory concern is the movement of manufacturing sites across borders, particularly the implications of such moves within the context of the UK’s regulatory framework following Brexit. To ensure compliance with stringent pharmacovigilance and manufacturing regulations, understanding the detailed requirements is crucial. This article elucidates the essential aspects of the regulatory affairs consideration…

Aligning UK, EU and US Labelling Decisions Without Confusing Stakeholders Aligning UK, EU and US Labelling Decisions Without Confusing Stakeholders In the dynamic landscape of pharmaceutical regulations, ensuring compliant labelling across different jurisdictions is a complex yet critical task for Regulatory Affairs (RA) professionals. This guide aims to clarify the relevant regulations and guidelines governing labelling decisions in the UK, EU, and US, providing a framework for navigating their unique requirements effectively. Understanding these regulations improves compliance and enhances communication with stakeholders regarding drug approval pathways and IQVIA pharmacovigilance practices. Regulatory Context The context for labelling decisions within regulatory affairs…

Handling Device-Drug Combination Products Under MHRA Rules Handling Device-Drug Combination Products Under MHRA Rules The regulatory landscape for device-drug combination products is complex and continues to evolve, particularly following the UK’s exit from the European Union. The Medicines and Healthcare products Regulatory Agency (MHRA) oversees the regulation of these products in the UK, ensuring that they are safe, effective, and of high quality. This article serves as a comprehensive guide for regulatory affairs professionals involved in the management of these products within the framework of MHRA rules, addressing essential components such as relevant regulations, documentation, and agency expectations. Context Device-drug…

Inspection Readiness in the UK: Role of RA Alongside QA and PV Inspection Readiness in the UK: Role of RA Alongside QA and PV The landscape of pharmaceutical regulation in the UK has undergone significant transitions post-Brexit, particularly in the context of global regulatory frameworks. Understanding the intersection of Regulatory Affairs (RA), Quality Assurance (QA), and Pharmacovigilance (PV) is crucial for optimizing drug approval pathways and maintaining compliance. This article aims to explore the relevant regulations and agency expectations that guide these interactions and highlight decision points critical to inspection readiness. Context Regulatory Affairs (RA) serves as a bridge between…

Planning for Northern Ireland Alignment with EU Rules Post-Brexit Planning for Northern Ireland Alignment with EU Rules Post-Brexit Regulatory Affairs Context The landscape of regulatory affairs in the pharmaceutical sector has undergone significant transformation following the United Kingdom’s departure from the European Union. This transition particularly affects Northern Ireland, which continues to align closely with EU regulations under the Northern Ireland Protocol. This article aims to provide a detailed explanation of the regulatory obligations, agency expectations, and practical tips for maintaining compliance within this unique framework. Legal and Regulatory Basis The regulatory framework for pharmaceuticals in Northern Ireland is primarily…

How to Use MHRA Guidance, Blog Posts and Consultations in Regulatory Strategy How to Use MHRA Guidance, Blog Posts and Consultations in Regulatory Strategy The regulatory landscape for pharmaceuticals and biotechnology in the UK has undergone significant changes following Brexit. As the UK establishes its own regulatory framework, understanding the role of the Medicines and Healthcare products Regulatory Agency (MHRA) becomes essential for professionals working in regulatory affairs, particularly in the context of regulatory compliance consulting services. This article serves as a comprehensive guide to navigating MHRA guidance and its implications for regulatory strategy. Regulatory Context The MHRA is the…

Transitioning Legacy EU Licences to Standalone UK Authorisations Transitioning Legacy EU Licences to Standalone UK Authorisations As the UK transitions to its own regulatory framework following Brexit, pharmaceutical and biotechnology companies must navigate the complexities of transitioning legacy EU licences to standalone UK authorisations. This article serves as a comprehensive regulatory explainer manual designed for regulatory affairs, CMC, and labelling teams within the US and EU pharma sectors. It will detail pertinent regulations, guidelines, agency expectations, and best practices, thus enhancing your understanding of the regulatory and compliance consulting landscape for the UK post-Brexit. Context The exit of the UK…

Case Studies of UK-First or UK-Pilot Regulatory Strategies Case Studies of UK-First or UK-Pilot Regulatory Strategies Context The recent landscape of regulatory affairs has undergone significant transformations, particularly following the UK’s departure from the EU. This transition prompted the UK Medicines and Healthcare products Regulatory Agency (MHRA) to adapt its regulatory pathways to better align with its national priorities and encourage innovation within the pharmaceutical sector. Regulatory Affairs professionals must understand these changes and how they interact with global regulatory frameworks, particularly those of the FDA and EMA. Legal and Regulatory Basis The regulatory frameworks governing pharmaceutical products in the…

Governance Models for UK RA Accountability in Global Organisations Governance Models for UK RA Accountability in Global Organisations Context The regulatory landscape for pharmaceutical and biotech industries has become increasingly complex, particularly in the wake of Brexit. With the UK establishing its own regulatory framework distinct from the European Union (EU), organisations now face challenges in ensuring compliance with both UK and EU regulations. This article provides in-depth guidance on governance models relevant for Regulatory Affairs (RA) accountability, particularly focusing on structures that support compliance across global operations. Legal/Regulatory Basis Regulatory Affairs in the UK falls under the Medicines and…

Top Questions Global Teams Ask About UK Regulatory Pathways Post-Brexit Top Questions Global Teams Ask About UK Regulatory Pathways Post-Brexit Context The United Kingdom’s departure from the European Union in January 2020 has created a new regulatory landscape for pharmaceutical and biotechnology products. As the MHRA (Medicines and Healthcare products Regulatory Agency) takes the lead in managing drug approvals and regulations, global teams must adapt to ensure compliance and successful product launches in this new context. Navigating the intricacies of UK regulatory pathways post-Brexit is essential for stakeholders within Regulatory Affairs, CMC (Chemistry, Manufacturing, and Controls), and Labelling teams. Legal…